Transcriptomic deconvolution in cancer and other heterogeneous tissues remains challenging.
inadequate for a three-component model which is exponentially more complex: 1) There are two degrees of freedom in the mixing proportions, which is unidentifiable in a large set of genes that are not differentially expressed between any two components; and 2) In each iteration in the parameter search, we need to perform tedious numerical double integrations in order to calculate the full likelihood. The DeMixT algorithm introduced two new elements that helped ensure the estimation accuracy and efficiency (Figure 1b) . We first apply an optimization approach, iterated conditional modes (ICM) [4] , which cyclically maximizes the probability of each set of variables conditional on the rest, for which we have observed rapid convergence [4] to a local maximum. The ICM framework further enables parallel computing, which helps compensate for the expensive computing time used in the repeated numerical double integrations. However this is not sufficient for accurate parameter estimation. We observed that including genes that are not differentially expressed between the N 1 and N 2 components in the 3-component deconvolution can introduce large biases in the estimated π 1 and π 2 ( Supplementary Figure 1) , while the π T estimation is little unaffected. We therefore introduce a novel gene-set-based component merging approach (GSCM) (Figure 1b) . Here, we first select gene set 1, where µ 1,g ≈ µ 2,g , and run the 2-component model to estimate π T,i . Then we select gene set 2, where µ 1,g ≈ µ 2,g , and run the 3-component model with fixed π T from the equation above, to estimate {π 1,i , π 2,i }.
Our goal is to avoid searching in the relatively flat regions of the full likelihood (model unidentifiable, Supplementary Figure 2 ) and focus on regions where the likelihood tends to be convex. Using this approach, we not only improve the estimation accuracy, but also further reduce the computing time as only a small part of the entire parameter space needs to be searched.
Validation using data with known truth. We validated DeMixT in two datasets with known truth in proportions and mean expressions: a publicly available microarray dataset [21] generated using mixed RNA from rat brain, liver and lung tissues in varying proportions; and an RNA-seq dataset generated using mixed RNA from three cell lines, lung adenocarcinoma (H1092), cancer-associated fibroblasts (CAFs) and tumor infiltrating lymphocytes (TILs).
We used GSE19830 [21] as our first dataset for benchmarking. This microarray experiment was designed for expression profiling of samples from Rattus norvegicus with the Affymetrix Rat Genome 230 2.0 Array, including 30 mixed samples of liver, brain and lung tissues in 10 different mixing proportions with three replicates ( Supplementary Table 1 ). To run DeMixT, we used the samples with 100% purity to generate the reference profiles for the 4/23 N 1 -component, N 2 -component and T -component, respectively. We ran the deconvolution for the 30 mixed samples as three scenarios, respectively assuming the liver, brain and lung tissues to be the unknown T -component tissue. To generate the second dataset in RNA-seq, we performed a mixing experiment, in which we mixed mRNAs from the three cell lines: lung adenocarcinoma in humans (H1092), CAFs and tumor infiltrating lymphocytes (TILs), at different proportions to generate 32 samples, including 9 samples that correspond to three repeats of a pure cell line sample for the three cell lines (Supplementary Table 2 ). The RNA amount of each tissue in the mixture samples was calculated on the basis of real RNA concentrations tested in the biologist's lab. We assessed our deconvolution approach through a number of statistics, e.g., concordance correlation coefficients (CCCs), root mean squared errors (RMSEs), and a summary statistics for measuring the reproducibility of the estimated π across scenarios when a different component is unknown (see Methods). We Table 1 , Supplementary Tables 3-6 ).
Validation using LCM data. We then applied DeMixT to a "gold standard" validation dataset from real tumor tissue that has known proportions, mean expressions and individual component-specific expressions. This dataset (GSE97284) was generated at Dana Farber Cancer Institute through LCM experiments on tumor samples from patients with prostate cancer. It consists of 25 samples of isolated tumor tissues, 25 samples of isolated stromal tissues and 23 admixture samples [24] . LCM was performed on formalin-fixed paraffin embedded (FFPE) tissue samples from 23 prostate cancer patients, and microarray gene expression data were generated using the derived and the matching dissected stromal and tumor tissues (GSE97284 [23] ). Due to the low quality of the FFPE samples, we selected a subset of probes (see Methods), and ran DeMixT under a two-component mode. DeMixT Figure 7 ) and yielded standard deviation estimates that are close to those from the dissected tumor samples ( Supplementary Figure 8) . As a result, the DeMixT individually deconvolved expressions achieved high CCCs (mean= 0.96) for the tumor component ( Figure 3d and Supplementary Figure 9 ). The expressions for the stromal component were more variable than those for a common gene expression dataset, hence both DeMixT and ISOpure gave slightly biased estimates of the means and standard deviations.
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Application to The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma (HNSCC) data. A recent study of HNSCC showed that the infiltration of immune cells, both lymphocytes and myelocytes, is positively associated with viral infection in virus-associated tumors [13] . We downloaded HNSCC RNA-seq data from TCGA data portal [17] and ran DeMixT for deconvolution. We normalized the expression data with the total count method and filtered out genes with zero count in any sample. There was a total of 44 normal tissue and 269 tumors samples in the HNSCC dataset. We collected the infection information of human papillomavirus (HPV) infection status for the HNSCC samples. Samples were classified as HPV-positive (HPV+) using an empiric definition of the detection of > 1000 mapped RNA-Seq reads, primarily aligning to viral genes E6 and E7, which resulted in 36 HPV+ samples [17] . Since only reference samples for the stromal component are available from TCGA (i.e., 44 normal samples and 269 tumor samples), we devised an analytic pipeline for DeMixT to run successfully on the HNSCC samples (for details, see Methods and Supplementary Figure 10 ). In brief, we first used data from the HPV+ tumors to derive reference samples for the immune component, and then ran the three-component DeMixT on the entire dataset to estimate the proportions for both HPV-negative (HPV-) and HPV+ samples. For all tumor samples, we obtained the immune (mean = 0.22, standard deviation = 0.10), the tumor (mean = 0.64, standard deviation = 0.13), and the stromal proportions (mean = 0.14, standard deviation = 0.07; see Figure   4a ). The distribution of stromal proportions seems independent, whereas the tumor and immune proportions are inversely correlated. As expected, HPV+ tumor samples had significantly higher immune proportions than those that tested as HPV-, [7, 13] Figure 11 ). To further evaluate the performance of our deconvolved expression levels, we performed differential expression tests for immune versus stromal tissue and immune versus tumor tissue, respectively, on 63 infiltrating immune cell-related genes (CD and HLA genes). For example, Figure 4c illustrates that the deconvolved expressions were much higher in the immune component than in the other two components for three important immune marker genes, CD4, CD14, and HLA-DOB. Overall, 51 out of 63 genes were significantly more highly expressed in the immune component than in the other two components (adjusted p-values are listed in Supplementary Data 1; also see Figure 4d ).
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Conclusions
In this work, we have presented a novel statistical method and software, DeMixT (R package at https://github.com/wwylab/DeMixT), for dissecting a mixture of tumor, stromal and immune cells bsed on the gene expression levels, and providing an accurate solution. Our method allows us to simultaneously estimate both cell-type-specific proportions and reconstitute patient-specific gene expression levels with little prior information. Distinct from the input data of most other deconvolution methods, our input data consist of gene expressions from 1) observed mixtures of tumor samples and 2) a set of reference samples from p − 1 compartments (where p is the total number of compartments).
Our output data provides the mixing proportions, the means and variances of expression levels for genes in each compartment, as well as the expression levels for each gene in each compartment and each sample. The full gene-compartment sample-specific output allows for the application of all pipelines previously developed for downstream analyses, such as clustering and feature selection methods in cancer biomarker studies, still applicable to the deconvolved gene expressions. We achieved this output by modeling compartment-specific variance and addressing the associated inferential challenges. DeMixT addresses the transcriptomic deconvolution in two steps. In the first step, we estimate the mixing proportions and the gene-specific distribution parameters for each compartment, using the ICM method, which can quickly converge. We further proposed a novel gene-set-based component merging (GSCM) approach and integrated it with ICM for the three-component deconvolution, in order to substantially improve model identifiability and computational efficiency. In the second step, we reconstitute the expression profiles for each sample and each gene in each compartment based on the parameter estimates from the first step. The success of the second step relies largely on the success of the first. We have overcome the otherwise significant computational burden for searching the high-dimensional parameter space and numerical double integration, due to our explicit modeling of variance, through parallele computing and gene set-based componment merging. On a PC with a 3.07 GHz Intel Xeon processor with 20 parallel threads, DeMixT takes 14 minutes to complete the full three-component deconvolution task of a dataset consisting of 50 samples and 500 genes (see Table 2 ). Our method can be applied to other data types such as proteomic data. It can be extended to p > 3.
We have used a series of experimental datasets to validate the performance of DeMixT.
These datasets were generated from a mixture of normal tissues, a mixture of human cell 7/23 lines, and LCM of FFPE tumor samples. DeMixT succeeded in recapitulating the truth in all datasets. We further demonstrated the tumor-stroma-immune deconvolution by DeMixT using TCGA HNSCC data. We were able to correlate our immune proportion estimates with the available HPV infection status in HNSCC, as is consistent with previous observations that a high level of immune infiltration appears with viral infection in cancer [12] . For this dataset, DeMixT is the first to provide a triangular view of tumor-stroma-immune proportions (Figure 4a) , the interesting dynamics of which may shed new light on the prognosis of HNSCC.
Gene selection is important for the success of deconvolution in both 2-component and 3-component models for DeMixT, and for any other methods. In a 2-component setting, we observed that both variances and mean differences in expression levels between the two components for each gene can affect how accurately the mixing proportions are estimated, while not all genes are needed for the proportion estimation. We therefore suggested selecting genes that have moderate variances and large differences between two components to estimate proportions. In a 3-component setting, using the gene-set-based component merging (GSCM) approach to reduce to a pseudo-2-component problem, we are able to apply a similar strategy. Currently our gene selection and GSCM strategy follow the principle of focusing on a subspace of the high-dimensional parameters for model identifiability, but are ad hoc and may need modification across datasets. Our future work will be to systematically evaluate the impact of each set of high-dimensional parameters on the full likelihood underlying our convolution model, and search for a unified gene selection method for the deconvolution of datasets that range over a wide spectrum of biological phenomena.
The reference gene-based deconvolution is popular for estimating immune subtypes within immune cells [14, 18] . Our method does not require reference genes which we consider as difficult to obtain for the tumor component; however DeMixT can take reference genes when available. With the reference sample approach, we assume the first p-1 compartments in the observed mixture to be similar to those in reference samples, while the remaining compartment is unknown, and so it may end up capturing most of the heterogeneity. The reference samples can be derived from historical patient data or from the corresponding healthy tissues, such as data from GTEx [16] (e.g. RNA-seq data from sun-exposed skin as reference samples for melanoma, unpublished results). Furthermore, each of the three components may contain more than one type of cell, in particular, the immune component.
It was reported that although heterogeneous, the relative proportions of immune cell subtypes within the immune component are consistent across patient samples [10] , which 8/23 supports our approach that models the pooled immune cell population using one distribution. Further development of DeMixT will account for subpopulations of immune cells in the convolution model, which will be a natural extension of the current model.
Finally, the performance of DeMixT will be optimized when the data analysis practice is linked with the cancer-specific biological knowledge.
Methods Model
Let Y ig be the observed expression levels of the raw measured data from clinically derived malignant tumor samples for gene g, g = 1, · · · , G and sample i, i = 1, · · · , S. G denotes the total number of probes/genes and S denotes the number of samples. The observed expression levels for solid tumors can be modeled as a linear combination of raw expression levels from three components:
Here N 1,ig , N 2,ig and T ig are the unobserved raw expression levels from each of the three components. We call the two components for which we require reference samples the We let π 1,i denote the proportion of the N 1 -component, π 2,i denote the proportion of the N 2 -component, and 1 − π 1,i − π 2,i denote the proportion of the T-component. We assume that the mixing proportions of one specific sample remain the same across all genes.
Our model allows for one component to be unknown, and therefore does not require reference profiles from all components. A set of samples for N 1,ig and N 2,ig , respectively, needs to be provided as input data. This three-component deconvolution model is applicable to the linear combination of any three components in any type of material. It can also be simplified to a two-component model, assuming there is just one N -component. For application in this paper, we consider tumor (T ), stromal (N 1 ) and immune components (N 2 ) in an admixed sample (Y ).
Following the convention that log 2 -transformed microarray gene expression data follow a normal distribution, we assume that the raw measures N 1,ig ∼ LN (µ N1g , σ 2 N1g ), 9/23
where LN denotes a log 2 -normal distribution and σ 2 N1g ,σ 2 N2g ,σ 2 T g reflect the variations under log 2 -transformed data [2, 15] . Consequently, our model can be expressed as the convolution of the density function for three log 2 -normal distributions. Because there is no closed form of this convolution, we use numerical integration to evaluate the complete likelihood function (see the full likelihood in the Supplementary Materials).
The DeMixT algorithm for deconvolution
DeMixT estimates all distribution parameters and cellular proportions and reconstitutes the expression profiles for all three components for each gene and each sample, as shown in equation (1) . The estimation procedure (summarized in Figure 1b ) has two main steps as follows.
Obtain a set of parameters {π
to maximize the complete likelihood function, for which {µ N1,g , σ N1,g , µ N2,g , σ N2,g } G g=1 were already estimated from the available unmatched samples of the N 1 and N 2 component tissues. This step is described in further details below in parameter estimation and the GSCM approach.
2. Reconstitute the expression profiles by searching each set of {n 1,ig , n 2,ig } that maximizes the joint density of N 1,ig , N 2,ig and T ig arg max n1,ig,n2,ig φ( y ig −π 1,i n 1,ig −π 2,i n 2,ig
where φ(.|µ, σ 2 ) is a log2-normal distribution density with location parameter µ and scale parameter σ.
In step 2, we combined the golden section search method with successive parabolic interpolations to find the maximum of the joint density function with respect to n 1,ig and n 2,ig that are positively bounded and constrained byπ 1,i n 1,ig +π 2,i n 2,ig ≤ y ig . The value of t ig is solved as y ig −π 1,i n 1,ig −π 2,i n 2,ig .
Parameter estimation using iterated conditional modes (ICM)
In step 1, the unknown parameters to be estimated can be divided into two groups:
gene-wise parameters, {µ T , σ T } G g=1 , and sample-wise parameters, {π 1 , π 2 } S i=1 . These two groups of parameters are conditionally independent (Figure 1b) .
For each pair of gene-wise parameters, we have
and similarly for each pair of sample-wise parameters, we have
These relationships allow us to implement an optimization method, ICM, to iteratively derive the conditional modes of each pair of gene-wise or sample-wise parameters, conditional on the others [4] . Here, π 1 , π 2 are constrained between 0 and 1, and µ T , σ T are positively bounded. We combined a golden section search and successive parabolic interpolations to find a good local maximum [5] in each step. As shown by Besag [4] , for ICM, the complete likelihood never decreases at any iteration and the convergence to the local maximum is guaranteed. Our ICM implementation is described in Figure 5 .
The GSCM approach to improve model identifiability
Due to the high dimension of the parameter search space, and often flat likelihood surfaces in certain regions of the true parameters (e.g., µ 1 ≈ µ 2 ) that will be encountered by ICM ( Supplementary Figure 2) , we have developed a GSCM approach (illustrated in Figure   1b ) to focus on the hilly part of the likelihood space. This reduces the parameter search space and improves the accuracy and computational efficiency. Here, we describe our general strategy. As there are large variations in the number of genes that are differentially expressed across datasets, the actual cutoffs may be adjusted for a given dataset.
Stage 1 We first combine the N 1 and N 2 components and assume a two-component mixture instead of three. This allows us to quickly estimate π T .
a: We select a gene set containing genes with small standard deviations (< 0.1 or 0.5) for both the N 1 and N 2 components. Among these genes, we further select genes with LN 1g ≈ LN 2g (mean difference < 0.25 or 0.5), where the LN is the sample mean for the 11/23 log2-transformed data. Within this set, we further select genes with the largest sample standard deviations of Y g (top 250), suggesting differential expression between T and N .
b: We run DeMixT in the two-component setting to estimate µ T g , σ 2 T g and π T . b: We run DeMixT in the three-component setting over the selected genes to estimate π 1 and π 2 given π T .
c: We estimate the gene-wise parameters for all genes given the fixed π's. Finally, given all parameters, per gene per sample expression level, n 1,ig , n 2,ig and t ig are reconstituted.
Simulation study for the GSCM approach
To demonstrate the utility of GSCM for parameter estimation, we simulated a dataset with expression levels from 500 genes and 90 samples, 20 of pure N 1 -type, 20 of pure N 2 -type and 50 mixed samples. For the 50 mixed samples, we generated their proportions for all three components (π 1 , π 2 , π T ) ∼ Dir (1, 1, 1) , where Dir is a Dirichlet distribution. For each mixed sample, we simulated expression levels of 500 genes for the N 1 and T-component from a log 2 -normal distribution with µ N1g and µ T g from N [0,+∞] (7, 1.5 2 ), and with equal variance.
For the N 2 -component, we generated µ N2g from µ N2g + d g , where d g ∼ N [−0.1,0.1] (0, 1.5 2 )
for 475 genes (μ N 1g ≈μ N 2g ) and d g ∼ N [0.1,3] (0, 1.5 2 ) ∪ N [−3,−0.1] (0, 1.5 2 ) for 25 genes (μ N 1g ≈μ N 2g ). Then we mixed the N 1 , N 2 and T-component expression levels linearly at the generated proportions according to our convolution model. We created a full matrix consisting of 20 N 1 -type reference samples (generated separately from the N 1 distribution), 20 N 2 -type reference samples (generated separately from the N 2 distribution) and 50 mixed samples at each simulation and repeated the simulation 100 times for each of the three variance values σ ∈ {0.1, 0.3, 0.5} to finally obtain 300 simulation repeats. We first ran
DeMixT with GSCM, where we used 475 genes with simulatedμ N 1g ≈μ N 2g to run the two-component deconvolution (N versus T ) and used the remaining 25 genes to run the three-component deconvolution with estimatedπ T . We also ran DeMixT without GSCM 12/23 using all 500 genes. RMSEs between estimated and true proportions for all mixed samples were calculated for each of the two runs: with and without GSCM.
Data analysis
All analyses were performed using the open-source environment R (http://cran.r-project.org). Documentation (knitr-html) of all scripts is provided at the GitHub repository.
Summary statistics for performance evaluation
Concordance correlation coefficient (CCC). To evaluate the performance of our method, we use the CCC and RMSE. The CCC ρ xy is a measure of agreement between two variables, x and y, and is defined as ρ xy = 2ρσxσy σ 2
x +σ 2 y +(µx−µy) 2 , where µ and σ 2 are the corresponding mean and variance for each variable, and ρ is the correlation coefficient between the two variables.
We calculate the CCC to compare the estimated and true proportions to evaluate the proportion estimation. We also calculate the CCC to compare the deconvolved and observed expression values (log 2 -transformed).
Measure of reproducibility.
To assess the reproducibility of the estimated π across scenarios when the different components are unknown (i.e., three scenarios for a three-component model with one unknown component), we define a statistic
is the estimated value for the k-th scenario and π i is the truth for sample i. S denotes the sample size and K is the number of scenarios. This measures the variations in the estimation errors across different scenarios. We consider a method with a smaller R as more reproducible and therefore more desirable.
Mixed tissue microarray dataset
We downloaded dataset GSE19830 [21] from the GEO browser. We used the R package {affy} to summarize the raw probe intensities with quantile normalization but without background correction as recommended in previous studies [14] . We evaluated the performance of DeMixT with regard to tissue proportions and deconvolved expression levels on the set of genes that were selected based on the GSCM approach. Specifically, we 13/23 selected genes with sample standard deviation < 0.1 in N 1 and N 2 components, among which we used those with LN 1g − LN 2g < 0.25 for running the 2-compoment model, and used the top 250 genes with largest LN 1g − LN 2g and largest sample standard deviation in Y for running the 3-component model. Then we ran ISOpure for the purpose of comparison.
Mixed cell line RNA-seq dataset
This dataset was generated in house by mixing RNAs from three cell lines at fixed proportions. We mapped raw reads generated from paired-end Illumina sequencing to the human reference genome build 37.2 from NCBI through TopHat (default parameters and supplying the -G option with the GTF annotation file downloaded from the NCBI genome browser). The mapped reads obtained from the TopHat output were cleaned by SAMtools to remove improperly mapped and duplicated reads. We then used Picard tools to sort the cleaned SAM files according to their reference sequence names and create an index for the reads. The gene-level expression was quantified by applying the R packages GenomicFeatures and GenomicRanges. We generated a reference table from the human reference genome hg19 and then used the function findOverlaps to count the number of reads mapped to each exon for all the samples. This count dataset was pre-processed by total count normalization, and genes that contained zero counts were removed. The pre-processed count data were used as input for DeMixT and ISOpure.
We performed the same GSCM step as in the analysis of mixed tissue microarray data.
Laser-capture microdissection (LCM) prostate cancer FFPE microarray dataset
This dataset was generated at the Dana Farber Cancer Institute (GSE97284 [24] ). Radical prostatectomy specimens were annotated in detail by pathologists, and regions of interest were identified that corresponded to benign epithelium, prostatic intraepithelial neoplasia (abnormal tissue that is possibly precancerous), and tumor, each with its surrounding stroma. These regions were laser-capture microdissected using the ArcturusXT system (Life Technologies). Additional areas of admixed tumor and adjacent stromal tissue were taken.
RNA was extracted by AllPrep (Qiagen) and quantified by RiboGreen assay (Life Technology). RNA labeling was performed using the SensationPlus FFPE method (Affymetrix) and hybridized to Affymetrix Gene Array STA 1.0.
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FFPE samples are known to generate overall lower quality expression data than those from fresh frozen samples. We observed a small proportion of probesets that presented large differences in mean expression levels between the dissected tissues: tumor (T ) and stroma (N ) in this dataset ( Supplementary Table 7 ). Only 53 probesets presented a mean difference (|T − N |) > 1, as compared to 10, 397 probesets in GSE19830. We therefore chose the top 80 genes with the largest mean differences and ran both DeMixT and ISOpure under two settings: tumor unknown and stroma unknown.
TCGA HNSCC data
We downloaded RNA-seq data for HNSCC from TCGA data portal (https://portal.gdc.cancer.gov/). There was a total of 44 normal and 269 tumors samples for HNSCC. We collected the information of HPV infection for the HNSCC samples. Samples were classified as HPV+ using an empiric definition of detection of > 1000 mapped RNA-seq reads, primarily aligning to viral genes E6 and E7, which resulted in 36 HPV+ samples [17] . We then devised a workflow to estimate the immune cell proportions ( Supplementary Figure 8) . Our workflow included three steps. The downloaded normal samples provided reference profiles for the stromal component in each step. We first downloaded stromal and immune scores from single-sample gene set enrichment analysis for all of our tumor samples [25] and selected 9 tumor samples with low immune scores (< −2) and high stromal scores (> 0), which suggested that these samples were likely low in immune infiltration. We then ran DeMixT under the two-component mode on these samples, generating the deconvolved expression profiles for the tumor and stromal components. We used these profiles as reference samples for running DeMixT under the three-component mode in the 36 HP V + samples, generating deconvolved expression profiles for the immune component. In these two steps, we used deconvolved profiles that have smaller estimated standard variations as the reference profiles for the next step. We then ran DeMixT under the three-component mode on all 269 samples with reference profiles from normal samples and the deconvolved immune component. We calculated p-values (Benjamini-Hochberg corrected [3] ) for the differential test of deconvolved expressions for the immune component versus the stromal component, and for the immune component versus the tumor component, respectively, on a set of 63 immune marker genes.
We performed gene selection in the GSCM approach (as described above), with a slightly larger threshold to account for the large sample size: sample standard deviation < 0.5 and 15/23 the top 500 genes for three-component deconvolution to estimate the π's. whereμ N1g ≈μ N2g and π T is given by the prior step, in order to estimate π 1 and π 2 . Sample-wise {⇡ 1,i } i : S Gene-wise {µ T g , T g } g : 2 ⇥ G 2: Initialize:
{µ T g , T g } G g=1 = µ 0 , 0 3: for iteration t = 1, · · · , T do, 4: a. update {⇡ 1,i } S i=1 5:
for each sample i = 1, · · · , S do parallel for each gene g = 1, · · · , G do parallel end for 12: end for Algorithm 2 Performing ICM for three-component 1: Parameter:
Sample-wise {⇡ 1,i , ⇡ 2,i } i : 2 ⇥ S Gene-wise {µ T g , T g } g : 2 ⇥ G 2: Initialize:
{µ T g , T g } G g=1 = µ 0 , 0 3: for iteration t = 1, · · · , T do, 4: a. update {⇡ 1,i , ⇡ 2,i } S i=1 5:
for each sample i = 1, · · · , S do parallel for each gene g = 1, · · · , G do parallel 
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